13924-96-4

Basic information

• Product Name: Pyrazinecarboxamide, 4,5-dihydro-5-oxo
• Synonyms: 5-Hydroxypyrazinamide;Pyrazinecarboxamide, 4,5-dihydro-5-oxo
• CAS NO: 13924-96-4
• Molecular Formula: C₅H₅N₃O₂
• Molecular Weight: 139.1121
• Mol File: 13924-96-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 292-295 °C
• Boiling Point: 659 °C at 760 mmHg
• Flash Point: 352.4 °C
• Appearance: /
• Density: 1.63 g/cm³
• Vapor Pressure: 5.65E-18mmHg at 25°C
• Refractive Index: 1.696
• PKA: 10.69±0.40(Predicted)
• CAS DataBase Reference: Pyrazinecarboxamide, 4,5-dihydro-5-oxo(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazinecarboxamide, 4,5-dihydro-5-oxo(13924-96-4)
• EPA Substance Registry System: Pyrazinecarboxamide, 4,5-dihydro-5-oxo(13924-96-4)

Safety Data

• Hazardous Substances Data: 13924-96-4(Hazardous Substances Data)

Usage

Description

Pyrazinecarboxamide, 4,5-dihydro-5-oxo, also known as 5-Hydroxypyrazinecarboxamide, is a metabolite derived from Pyrazinamide, an antibacterial agent with specific activity against Mycobacterium tuberculosis. Pyrazinecarboxamide, 4,5-dihydro-5-oxo plays a significant role in the biotransformation process of the parent drug, contributing to its overall efficacy in treating tuberculosis.

Uses

Used in Pharmaceutical Industry:
Pyrazinecarboxamide, 4,5-dihydro-5-oxo is used as a metabolite in the development and understanding of the mechanism of action for [application reason] Pyrazinamide, an antibacterial agent specifically targeting Mycobacterium tuberculosis. Its role in the biotransformation process aids in enhancing the drug's efficacy and understanding its mode of action in treating tuberculosis.
Used in Research and Development:
In the field of medical research, Pyrazinecarboxamide, 4,5-dihydro-5-oxo is used as a key compound for studying the metabolic pathways and interactions of Pyrazinamide. This helps researchers to better understand the drug's pharmacokinetics and pharmacodynamics, potentially leading to the development of improved treatments for tuberculosis and other related diseases.
Used in Drug Metabolism Studies:
Pyrazinecarboxamide, 4,5-dihydro-5-oxo is utilized in drug metabolism studies to investigate the biotransformation processes of various drugs, particularly those with similar chemical structures or mechanisms of action. This information can be crucial in predicting potential drug-drug interactions, assessing the safety and efficacy of new drug candidates, and optimizing drug dosages for patients.

InChI:InChI=1/C5H5N3O2/c6-5(10)3-1-8-4(9)2-7-3/h1-2H,(H2,6,10)(H,8,9)

Upstream product

• 77168-76-4 3-carbamoyl-1,6-dihydro-6-oxo-2-pyrazinecarboxylic acid 
• 57005-60-4 1,6-dihydro-6-oxo-2,3-pyrazinedicarbonitrile 

Downstream Products

• 34604-60-9 4,5-dihydro-5-oxo-2-pyrazinecarboxylic acid 
• 13924-95-3 methyl 4,5-dihydro-5-oxo-2-pyrazinecarboxylate 
• 77168-80-0 5,6-dihydroxy-2-pyrazinecarboxylic acid 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 

Relevant articles and documents

Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents

To explore the application potential of dual prodrug strategies in the development of anti-HCV agents, a variety of sofosbuvir derivatives with modifications at the C4 or N3 position of the uracil moiety were designed and synthesized. Some compounds exhibited potent anti-HCV activities, such as 4e and 8a–8c with similar EC50 values (0.20–0.22 μM) comparative to that of sofosbuvir (EC50 = 0.18 μM) in a genotype 1b based replicon Huh-7 cell line. Moreover, 8b displayed a good human plasma stability profile, and was easily metabolized in human liver microsomes expectantly. On the other hand, aiming to discover novel anti-HCV nucleosides, pyrazin-2(1H)-one nucleosides and their phosphoramidate prodrugs were investigated. Several active compounds were discovered, such as 25e (EC50 = 7.3 μM) and S-29b (EC50 = 19.5 μM). This kind of nucleosides were interesting and would open a new avenue for the development of antiviral agents.